Regulatory

• Preparation of Clinical Overviews (Expert Reports) for new molecular entities and Prescription only to OTC switches
• Preparation of summaries of efficacy, safety and  clinical pharmacology for Common Technical Documents
• Devising the Regulatory Strategy
• Briefing and Background documents prior to IND/CTA, end of Phase II, pre-MAA/NDA
• Presentations and Discussion with Regulatory Authorities